The article evaluates several medical products, including the antinausea drug granisletron hydrochloride tablets from Teva Pharmaceuticals, the oral alkylating agent temozolomide Temodar from Schering-Plough Corp. and the clotting solution Recothrom from ZymoGenetics Inc.